KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

Abstract Immunotherapy has become a prominent first-line cancer treatment strategy. In non-small cell lung cancer (NSCLC), the expression of PD-L1 induces an immuno-suppressive effect to protect cancer cells from immune elimination, which designates PD-L1 as an important target for immunotherapy. Ho...

Full description

Bibliographic Details
Main Authors:	Jinghan Li, Daiwang Shi, Siyi Li, Xiang Shi, Yu Liu, Yi Zhang, Gebang Wang, Chenlei Zhang, Tian Xia, Hai-long Piao, Hong-Xu Liu
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-02-01
Series:	Cell Death and Disease
Online Access:	https://doi.org/10.1038/s41419-024-06563-3

Similar Items

926 Immune profiling of KEAP1-deficient NSCLC: development of therapeutic strategies to overcome resistance to immunotherapy
by: Linghua Wang, et al.
Published: (2021-11-01)

Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC
by: Michelle Shiller, et al.
Published: (2024-12-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)

XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
by: Xuanzong Li, et al.
Published: (2021-10-01)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
by: Fenglong Bie, et al.
Published: (2022-02-01)

Cold exposure induced oxidative stress and apoptosis in the myocardium by inhibiting the Nrf2-Keap1 signaling pathway
by: Peifang Cong, et al.
Published: (2018-02-01)

RASSF1A Enhances Chemosensitivity of NSCLC Cells Through Activating Autophagy by Regulating MAP1S to Inactivate Keap1-Nrf2 Pathway
by: Wang J, et al.
Published: (2021-01-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Double Knockdown of PHD1 and Keap1 Attenuated Hypoxia-Induced Injuries in Hepatocytes
by: Jing Liu, et al.
Published: (2017-05-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration
by: Chenyue Zhang
Published: (2021-06-01)

Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model
by: Tianyun Qiao, et al.
Published: (2021-03-01)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
by: Long Ma, et al.
Published: (2021-08-01)

Inhibition of MALAT1 facilitates ROS accumulation via the Keap1/HO-1 pathway to enhance photodynamic therapy in secondary hyperparathyroidism
by: Ying Wen, et al.
Published: (2025-04-01)

DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1‐Mediated NRF2 Ubiquitination
by: Xin Wang, et al.
Published: (2023-05-01)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01)

Generation and characterization of keap1a- and keap1b-knockout zebrafish
by: Vu Thanh Nguyen, et al.
Published: (2020-09-01)

EGFR Mutation Status and PD-L1 Expression in Patients ≤40 Years Old with NSCLC
by: HU Mingming, et al.
Published: (2022-07-01)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
by: Haowei Wang, et al.
Published: (2023-06-01)

Disruption of the Keap1-mTORC2 axis by cancer-derived Keap1/mLST8 mutations leads to oncogenic mTORC2-AKT activation
by: Yingji Chen, et al.
Published: (2023-11-01)

Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis
by: Zhang C, et al.
Published: (2019-05-01)

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC
by: Hong Liu, et al.
Published: (2024-12-01)

Feasibility of nodal classification for non‐small cell lung cancer by merging current N categories with the number of involved lymph node stations
by: Wei Chen, et al.
Published: (2019-07-01)

UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis
by: Liang Zhao, et al.
Published: (2022-11-01)

Metal-Phenolic network pH-Sensitive Nanoparticle-Enabled Chemo/Chemodynamic therapy for lung cancer
by: Daiwang Shi, et al.
Published: (2023-07-01)

Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
by: Honghui Zhao, et al.
Published: (2023-03-01)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
by: Zi‐Ying Chen, et al.
Published: (2023-01-01)

Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
by: Meiling Gong, et al.
Published: (2020-06-01)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
by: Lars Henning Schmidt, et al.
Published: (2015-01-01)

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
by: Ling Yi, et al.
Published: (2023-03-01)

Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC
by: Xin Zheng, et al.
Published: (2024-12-01)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
by: Liu, Y, et al.
Published: (2021)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
by: Yi Liu, et al.
Published: (2021-11-01)

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy
by: Francis Proulx-Rocray, et al.
Published: (2023-01-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis
by: Jian Zhang, et al.
Published: (2023-06-01)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
by: Xiaomei Liu, et al.
Published: (2020-04-01)

What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
by: Ruichen Cui, et al.
Published: (2022-10-01)

Cordycepin alleviates osteoarthritis by inhibiting chondrocyte ferroptosis via Keap1/Nrf2 axis
by: Jianlei Li, et al.
Published: (2024-02-01)

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
by: Vera Kloten, et al.
Published: (2019-08-01)